Categories
Market Outlook Market Reports Market Research

Global Oxycodone Hydrochloride Market is expected to grow at a CAGR of 1.8% from 2020 to 2027

Oxycodone hydrochloride binds on the mu-receptors present in the central nervous systems and mimics the endogenous opiates. It is under strict government regulation and supervision to prevent its abuse of opioid addiction in patients using it for the long term in managing chronic pain.

Acute pain management is spearheading the clinical application segment for the oxycodone market. The nature of acute pain is sudden and episodic, it last form a few weeks to almost six months. Medical ailments such as surgery, broken bones, dental works, mild lacerations, and burns, etc. are associated with acute pain. Physicians usually prescribe a low dose of an opioid analgesic is given to patients for treating the pain and the patient can resume a normal lifestyle. Chronic pain is gaining tremendous traction owing to the rising prevalence of cancer and musculoskeletal disorders worldwide. Chronic pain is continuous and throbbing in nature, medical conditions such as arthritis, fibromyalgia, cancer, etc. are associated with chronic pain. It is prescribed in combination with other painkillers with dose adjusted to negate any possible opioid addiction due to its long term use.

Browse the full report Oxycodone Hydrochloride Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027 at https://www.atlanticmarketresearch.com/oxycodone-hydrochloride-market

Hospital pharmacy is currently dominating the distribution channel segment for the oxycodone hydrochloride market.  Stringent regulation and supervision are maintained regarding the compounding of Opioid analgesics as a medicine for pain management. Hospital pharmacist ensures accurate drug posology in accordance with a doctor’s prescription to negate opioid addiction. Retail pharmacy is going to register comfortable market growth on account of the availability of different combinations of opioid analgesics with other NSAIDS in generic versions. The ability to cater to drugs at discounted prices to poor patients accentuates its market growth.

North America is leading the geography segment for the oxycodone hydrochloride market. As per the research citings presented by the American Cancer Society (ACS) approximately 606,520 cancer deaths will occur in the United States by 2020. Domicile of key players such as Pfizer, Inc., Apotex Corporation, Purdue Pharma, etc. further propels its market growth in the region. The market growth in the European region is primarily driven by the rising prevalence of musculoskeletal disorders. As per the latest information furnished by the World Health Organization (WHO), approximately 24.7% of workers in the European Union complain of backache and 22.8% with muscular pain respectively. A combination dose of opioid analgesic and other painkillers are employed to manage pain associated with musculoskeletal disorders in the region. Asia Pacific is set to register comfortable market growth in the region on account of the rising prevalence of occupational hazards and cancer patients and effective implementation of guidelines pertaining to the judicious use of opioid analgesic as a pain management therapy.

Pharmaceutical companies actively engaged in the manufacturing of oxycodone hydrochloride are Pfizer, Inc., Teva Pharmaceutical Industries Ltd, Apotex Corporation, Mallinckrodt Pharmaceuticals, Purdue Pharma, Daiichi Sankyo Company Limited., Acura Pharmaceuticals., Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., and Siegfried AG.

Market Key Takeaways:

  • Rising prevalence of cancer and musculoskeletal disorder patients suffering from acute and chronic pain
  • Technological advancement in the formulation and development of opioid alkaloids with other painkillers to negate any possible opioid addiction due to its long term use
  • Affordable reimbursement scenario for oxycodone hydrochloride formulation used in pain management therapy

About Atlantic Market Research

Atlantic Market Research is the largest provider of market research and consulting services.

Research and consulting services of Atlantic Market Research help businesses across the globe navigate the challenges in a rapidly growing marketplace with confidence. Our customized and syndicated market research reports deliver sufficient insights that drive sustainable growth.

Contact:
Mr. Trevor Wilson
Atlantic Market Research
911 Central Ave #268
Albany, NY 12206, USA

Website: https://www.atlanticmarketresearch.com
Email: [email protected]

Categories
Market Reports Market Research

Global Enzymatic Wound Debridement Market Is Expected to Grow at A CAGR of 6.1% From 2020 To 2027

Enzymatic wound debridement products comprise of papain, collagenase, fibrinolysis, and deoxyribonucleases. Papain is derived from the papaya fruit, collagenase form bacteria, and deoxyribonucleases and fibrinolysins from the bovine extracts. Technological advancement in the development of the enzymatic wound debridement products will further propel the market growth during the forecast period.

Acute wounds are reigning the type segment for enzymatic wound debridement market. The acute wounds comprise of the following types of wounds such as lacerations, burns, incisions, and punctures, etc. which is experienced by human beings at least once during their lifetime. Chronic wounds are expected to record rapid market growth during the forecast period owing to the rising prevalence of diabetic foot ulcers worldwide. A constant rise in the number of surgeries performed throughput the globe further propel its market growth.

Browse the full report Enzymatic Wound Debridement Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027 at https://www.atlanticmarketresearch.com/enzymatic-wound-debridement-market

Collagenase is currently dominating the product segment for enzymatic wound debridement market. Collagenase products are highly popular among surgeons owing to its ability to promote the granulation process to enhance the epithelialization of skin cells. It is critical in shifting the wound healing process from the inflammatory stage to the proliferative stage. A constant rise in diabetic foot ulcers and venous leg ulcers worldwide drives its market growth. Papain is considered the most suitable option for tending large wounds manifesting sepsis and cellulite. It is either used in combination with urea or saline solution depending on the degree of tissue necrosis at the wound site.

North America is currently leading the geography segment for enzymatic wound debridement market. The key factor responsible for its market growth is the rising prevalence of diabetic foot ulcers in the region. According to the recent statistics provided by the Center for Disease Control and Prevention (CDC), approximately 34.2 million people in the United States are suffering from diabetes. Furthermore, the presence of major players such as Mölnlycke Health Care AB, Coloplast Corp., ConvaTec Group, Plc., Medline Industries, Inc., etc. further accentuates the market growth in the region. Europe is in the 2nd position in the regional segment on account of the affordable reimbursement scenario for the enzymatic wound debridement products employed for the treatment of pressure ulcers in the region. Asia Pacific is anticipated to be the fastest-growing regional segment during the forecast period. Significant increase in the acute wounds associated with domestic accidents and constant rise in the chronic wounds associated with diabetic foot ulcers and pressure ulcers together drive the market growth in the Asia Pacific region.

Pharmaceutical manufacturers actively engaged in the production of enzymatic wound debridements are Mölnlycke Health Care AB., Smith & Nephew, Plc., ConvaTec Group, Plc., Coloplast Corp., Medline Industries, Inc., B. Braun Melsungen AG., Integra LifeSciences, PAUL HARTMANN Limited, Arobella Medical, LLC and Advancis Medical.

Market Key Takeaway:

  • Rising prevalence of diabetic foot ulcer worldwide
  • A constant rise in the number of surgeries performed worldwide
  • Supportive regulatory environment provided by the global healthcare agencies for the enzymatic wound debridement market

About Atlantic Market Research

Atlantic Market Research is the largest provider of market research and consulting services.

Research and consulting services of Atlantic Market Research help businesses across the globe navigate the challenges in a rapidly growing marketplace with confidence. Our customized and syndicated market research reports deliver sufficient insights that drive sustainable growth.

Contact:
Mr. Trevor Wilson
Atlantic Market Research
911 Central Ave #268
Albany, NY 12206, USA

Website: https://www.atlanticmarketresearch.com
Email: [email protected]

Categories
Market Outlook Market Reports Market Research

Global Chloroquine Products Market Is Expected to Grow At A CAGR of 4.0% from 2020 to 2027

Chloroquine exerts its pharmacological effect by inhibiting the action of heme polymerase which eventually results in the buildup of toxic heme in the plasmodium species. It also passively diffuses through the cell membrane and hence becomes protonated and raises the surrounding pH which prevents the virus particles from infusing and entering the cell and hence is currently being studied for its therapeutic efficacy in COVID-19 infection.

Protozoan infection is spearheading the clinical application segment for the chloroquine products market. Malaria is caused by the plasmodium species such as vivax, ovale, falciparum, and malariae, as per the latest statistics provided by the World Health Organization (WHO) in 2018, approximately 405 000 deaths due to malaria infection were reported worldwide. Sub-Saharan Africa, South Asia, and tropical rain forests are the regions were the highest mortality rate has been reported due to lack of medical provisions. Amebiasis is caused by the protozoan parasite Entamoeba histolytica in which the transmission is caused by the fecal-oral route, according to the latest information provided by the National Institute of Health (NIH), each year approximately 50 million cases of invasive E. histolytica infection are reported worldwide. Autoimmune diseases are expected to showcase sturdy market growth in the near future owing to the rising incidence of lupus erythematosus in the developed regions.

Browse the full report Chloroquine Products Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027 at https://www.atlanticmarketresearch.com/chloroquine-products-market

Hospital pharmacy is presently leading the distribution channel segment for the chloroquine products market. A long duration of action and a half-life of 20 to 60 days makes it imperative for accurate medicine dispensing by hospital pharmacists to prevent the occurrence of drug-related adverse events. Retail pharmacy is keen to register remarkable market growth during the forecast period owing to the availability of government-subsidized low-cost generic medicines in the developing region.

Asia Pacific is currently dominating the geography segment for the chloroquine products market. The rising prevalence of protozoan infection in the South East Asia region primarily drives the market growth. Poor sanitation, unhygienic food, and water are the primary causes for the occurrence of amoebiasis in the slum dwellings of the South Asian countries. Developing healthcare infrastructure and effective implementation of the treatment guidelines pertaining to protozoan infections together accentuate the market growth in the region. Latin America is 2nd in the regional segment on account of the plasmodium species infection in the far-flung rain forest areas. North America is anticipated to be the fastest-growing regional segment for the chloroquine products market. Developed healthcare infrastructure and the existence of major players such as Bayer AG, Sandoz, Inc., Teva Pharmaceutical Industries Ltd., etc determine the chloroquine product market growth in the region.

Pharmaceutical manufacturers actively engaged in the production of chloroquine products are Recipharm AB, Bayer AG, Sandoz, Inc., Teva Pharmaceutical Industries Ltd., Sanofi Aventis, IPCA Laboratories, Cadila Healthcare, Merck & Co., Inc., Indofarma and Alliance Pharmaceuticals.

Key Market Movements:

  • Rising prevalence of protozoan infection worldwide
  • Growing incidence of autoimmune diseases throughout the globe further accentuates the market growth
  • Nurturing regulatory environment provided by the global healthcare agencies for the sale and distribution of chloroquine products further drive the market growth

About Atlantic Market Research

Atlantic Market Research is the largest provider of market research and consulting services.

Research and consulting services of Atlantic Market Research help businesses across the globe navigate the challenges in a rapidly growing marketplace with confidence. Our customized and syndicated market research reports deliver sufficient insights that drive sustainable growth.

Contact:
Mr. Trevor Wilson
Atlantic Market Research
911 Central Ave #268
Albany, NY 12206, USA

Website: https://www.atlanticmarketresearch.com
Email: [email protected]

Categories
Market Outlook Market Reports Market Research

Global Psychiatric Medications Market is expected to grow at a CAGR of 2.7% from 2020 to 2027

Rigorous scientific research has led to substantial evidence of the involvement of 2 neurotransmitters to be linked with the pathophysiology of psychosis which is glutamate and dopamine. Researchers are of the opinion that if the abnormality in the glutamate and dopamine interaction is resolved in the early stages of the mental illness it can save a patient from entering into psychosis. Promising product pipeline will fortify the psychiatric market growth during the forecast period.

The treatment regimen for psychiatric disorders has undergone tremendous research and development over the last 5 decades eventually resulting in 3 generations of the drug class of psychiatric medications. First-generation comprises of Haldol and Navane which are popular since the 1960s but are rendered outdated due to their side effects such as drowsiness, nausea, and vomiting. Second generation psychiatric medications are dominating the drug class segment on account of their ability to block the dopamine pathways in the central nervous systems and hence are frequently prescribed for treating disorders such as schizophrenia and bipolar disorder. Abilify is the third generation psychiatric medication that is anticipated to grow at a rapid pace owing to its enhanced therapeutic efficacy and tolerability in patients suffering from mental disorders.

Browse the full report Psychiatric Medications Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027 at https://www.atlanticmarketresearch.com/psychiatric-medications-market

In the present situation, schizophrenia is dominating the application segment for the psychiatric medications market. The chief elements responsible for the occurrence of schizophrenia are insomnia, frequent mood swings, episodic bouts of depression, etc. Bipolar disorder is anticipated to grow at a rapid pace in the near future owing to the occurrence of clinical depression, significant euphoria, and distractibility experienced by the patients during his lifetime. According to the latest research citings brought forward by the World Health Organization (WHO), approximately 264 million people are suffering from depression across the globe.

North America is currently reigning the geography segment for the psychiatric medications market. The major factors responsible for its supreme market growth are the rising prevalence of depression across all age groups in the United States. As per the latest research citings brought forward by the Anxiety and Depression Association of America, in the United States, approximately 6.7% of the population is suffering from some form of depression. Effective implementation of treatment regimen and affordable reimbursement scenario together drive the psychiatric medications market growth in the region. Europe is placed in the 2nd position in the geography segment for the psychiatric medications market. As per the statistics brought forward by the World Health Organization (WHO), in Europe, approximately 110 million people suffer from some form of mental illness. The rising prevalence of the bipolar disorder in the Eastern European Region will provide a potential market for the psychiatric medications market in the region. The Asia Pacific is set to register sturdy growth during the forecast period on account of the rising prevalence of schizophrenia in middle-aged population, stressful lifestyle is likely to increase the number of people suffering from depression, thereby providing necessary growth impetus required for the psychiatric medications in the region.

Pharmaceutical companies actively engaged in the production of psychiatric medications are AstraZeneca, Plc., Allergan, Plc., GlaxoSmithkline, Plc., Bristol Myers Squibb Company, Eli Lilly & Company, Johnson & Johnson, Pfizer, Inc., Sumitomo Dainippon Pharma, Teva Pharmaceutical Company Limited and Merck KGaA.

Market Key Takeaways:

  • Significant rise in the mental disorders throughout the globe
  • Affordable reimbursement scenario for psychiatric medications
  • Promising drug pipeline likely to accentuate the psychiatric medications market growth during the forecast period

About Atlantic Market Research

Atlantic Market Research is the largest provider of market research and consulting services.

Research and consulting services of Atlantic Market Research help businesses across the globe navigate the challenges in a rapidly growing marketplace with confidence. Our customized and syndicated market research reports deliver sufficient insights that drive sustainable growth.

Contact:
Mr. Trevor Wilson
Atlantic Market Research
911 Central Ave #268
Albany, NY 12206, USA

Website: https://www.atlanticmarketresearch.com
Email: [email protected]

Categories
Market Reports Market Research

Global Macrophage Stimulating Protein Receptor Market is expected to grow at a CAGR of 8.1% from 2020 to 2027

Non-small cell lung cancer (NSCLC) is presently leading the clinical application segment for macrophage stimulating protein receptor market. NSCLC is highly heterogeneous at the molecular level and receptor tyrosine kinase signaling pathway is responsible to initiate mutations that eventually result in lung tumorigenesis. NSCLC is being treated successfully by suppressing the mutation at the receptor level by the tyrosine kinase inhibitors. Osteoporosis will be the fastest-growing clinical application during the forecast period due to the association of macrophage stimulating protein signaling pathway in breast cancer-induced osteoporosis in women by elevating the osteolytic bone metastasis respectively. Monoclonal antibodies are being developed to treat cancer-induced osteoporosis by preventing the development of osteoclasts.

Hospital pharmacy is spearheading the distribution channel segment for macrophage stimulating protein receptors market. In the developed regions the cancer patients entirely depend on the hospital pharmacist for dispensing tyrosine kinase inhibitors for the treatment of metastatic cancer, proper care is taken to maintain drug posology in accordance with the physician’s prescription. The retail pharmacy will register magnificent market growth in the near future on account of its ability to provide antineoplastic drugs at government-sponsored subsidized rates to customers.

Browse the full report Macrophage Stimulating Protein Receptor Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027 at https://www.atlanticmarketresearch.com/macrophage-stimulating-protein-receptor-market

North America is currently reigning the geography segment for macrophage stimulating protein receptor market. According to the latest statistics provided by the American Society for Clinical Oncology (ASCO), in 2019 approximately 135,720 U.S. citizens died due to lung cancer. Non-small cell lung cancer accounted for 85% of the death cases. Domicile of key players such as Amgen, Inc., Pfizer, Inc., Bristol-Myers Squibb Company, etc. accentuates the market growth in the region. Europe is in the second position owing to the collaboration between academic research institutes and biopharmaceutical companies to develop novel molecules to treat breast cancer-induced osteoporosis in women population in the region. Asia Pacific is keen to register rapid market growth owing to the developing infrastructure and rising prevalence of lung cancer in the Asia Pacific region.

Biopharmaceutical companies manufacturing drugs for treating cancer associated with the macrophage stimulating protein receptor signaling pathway are Advenchen Laboratories, LLC, ASLAN Pharmaceuticals, Bristol-Myers Squibb Company, Chia Tai Tianqing Pharmaceutical Group, Pfizer, Inc., SignalChem Lifesciences Corp., OSI Pharmaceuticals., Amgen, Inc., BeiGene Ltd. and Lead Discovery Center GmbH.

Market Key Takeaways:

  • Rising prevalence of non-small cell lung cancer associated with the macrophage stimulating protein receptor signaling pathway
  • RON kinase inhibitors are being developed for the treatment of breast cancer-induced osteoporosis in female population worldwide
  • Affordable reimbursement scenario for the antineoplastic drugs used for the treatment of tumorigenesis associated with tyrosine kinase receptor signaling pathway

About Atlantic Market Research

Atlantic Market Research is the largest provider of market research and consulting services.

Research and consulting services of Atlantic Market Research help businesses across the globe navigate the challenges in a rapidly growing marketplace with confidence. Our customized and syndicated market research reports deliver sufficient insights that drive sustainable growth.

Contact:
Mr. Trevor Wilson
Atlantic Market Research
911 Central Ave #268
Albany, NY 12206, USA

Website: https://www.atlanticmarketresearch.com
Email: [email protected]

Categories
Market Outlook Market Reports Market Research

Global Acetylcysteine Market Is Expected To Grow At A CAGR Of 4.7% From 2020 To 2027

N-acetylcysteine is a prodrug for cysteine which gets absorbed in the gastrointestinal tract and is critically important in the maintenance and replenishment of liver glutathione. It is available as intravenous injection, inhalation, coated tablets, etc. and is currently in demand as a dietary supplement for its potent antioxidant properties.

Acetaminophen overdose is currently leading the treatment segment for the acetylcysteine market. The key parameters contributing to its supreme market growth is a significant increase in the patients suffering from fever associated with the infectious disease throughout the globe. In such patients the acetaminophen overdose occurs due to non- compliance to doctor’s prescription and in few cases injudicious use of paracetamol as a pain killer confirms liver toxicity. Its primary objective is to maintain and replenish the glutathione reserves of the liver and promote the non-toxic metabolism of acetaminophen. Chronic obstructive pulmonary disease (COPD) is expected to register magnificent market growth during the forecast period. As per the research citings provided by the World Health Organization, COPD is currently the fifth largest cause of death worldwide. The major symptom pertaining to COPD is shortness in breath due to excess mucus secretion. Acetylcysteine inhalation is beneficial reducing the adhesiveness and viscosity of the mucus and promotes its expulsion from the lower respiratory tract.

Hospitals and clinics are dominating the end-user segment for the acetylcysteine market. Patients suffering from acetaminophen overdose need to be immediately hospitalized to start a treatment regimen of intravenous acetylcysteine to promote nontoxic metabolism of acetaminophen. Ambulatory surgical centers are estimated to register rampant market growth in the near future on account of its ability to stabilize patients suffering from chronic obstructive pulmonary disorders located in remote locations.

Browse the full report Acetylcysteine Market  – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027 at https://www.atlanticmarketresearch.com/acetylcysteine-market

North America presently spearheading the geography segment for the acetylcysteine market. According to the latest statistics provided by the National Institute for Health (NIH), approximately 700,000 people get hospitalized in the United States each year. Furthermore, the domicile of major players such as Fresenius Kabi USA, LLC, Arbor Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Sandoz, Inc., etc further bolsters the market growth in the region. Europe is the second-largest regional segment owing to the strategic collaboration between academic research institute and nutraceutical giants in the development of dietary supplements containing acetylcysteine endorsed for its potent antioxidant properties. Asia Pacific is anticipated to be the fastest-growing regional segment in the acetylcysteine market. Significant increase in the number of patients suffering from acetaminophen overdose owing to gross negligence with acetaminophen drug posology and flourishing generic drugs market together drive the acetylcysteine market growth in the region.

Pharmaceutical manufacturers actively engaged in the production of acetylcysteine are Fresenius Kabi USA, LLC, Arbor Pharmaceuticals LLC, Zambon Group, Sandoz, Inc., Menarini Group, Teva Pharmaceutical Industries Ltd., IBSA Farmaceutici., Sanofi S.A., Nippon Rika Co., Ltd., and Cipla Limited.

Market Key Takeaway:

  • Rising prevalence of acetaminophen overdose in patients suffering from fever associated with infectious disease
  • Significant increase in the number of patients suffering from chronic pulmonary obstructive disorder worldwide
  • Increasing demand for acetylcysteine as a dietary supplement owing to its potential antioxidant properties

About Atlantic Market Research

Atlantic Market Research is the largest provider of market research and consulting services.

Research and consulting services of Atlantic Market Research help businesses across the globe navigate the challenges in a rapidly growing marketplace with confidence. Our customized and syndicated market research reports deliver sufficient insights that drive sustainable growth.

Contact:
Mr. Trevor Wilson
Atlantic Market Research
911 Central Ave #268
Albany, NY 12206, USA

Website: https://www.atlanticmarketresearch.com
Email: [email protected]

Categories
Market Outlook Market Reports Market Research

Global Polyene Phosphatidylcholine Market Is Expected to Grow At A CAGR of 4.2% from 2020 to 2027

Polyene phosphatidylcholine is an unsaturated version of phosphatidylcholine which is derived from natural sources such as soybeans, eggs, sunflowers, mustard, etc. It is interchangeably mentioned as lecithin which is a different chemical moiety. It has a vital role in the transfer of phosphatidylcholine transfer protein (PCTP) within cell membranes and is the activation of enzymes having significance in the metabolic functions of the liver.

Liver diseases are reigning the clinical application segment for the polyene phosphatidylcholine market. According to the latest statistics provided by the National Institute of Health (NIH), it is estimated that approximately 50 million people worldwide are suffering from chronic liver disease. Additionally, the growing incidence of hepatitis B infection among the adult population across the globe further accelerates the market growth. Dietary supplements are gaining immense popularity since the last 2 decades on account of the rising public health awareness and technological advancement in the nutraceutical segment which together increases the demand for polyene phosphatidylcholine as a nutraceutical product.

Browse the full report Polyene Phosphatidylcholine Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027 at https://www.atlanticmarketresearch.com/polyene-phosphatidylcholine-market

Hospital pharmacy is representing the largest market share in the distribution channel segment for the polyene phosphatidylcholine market. It is commercially available as injectable and capsules and dosage vary as per the type of hepatic complications, therefore accurate drug compounding by hospital pharmacists is necessary in order to engage the occurrence of any side effects associated with overdose. Retail pharmacy is going to register steady market growth during the forecast period on account of the increasing demand for dietary supplements enriched with polyene phosphatidylcholine.

North America is currently dominating the geography segment for the polyene phosphatidylcholine market. Increasing demand for polyene phosphatidylcholine enriched nutritional supplements for its therapeutic efficacy in the treatment of ulcerative colitis, cognitive functions, etc. primarily drives the market growth in the region. According to the latest statistics provided by the Center for Disease Control and Prevention (CDC), approximately 1.8% of the adult population in the United States are diagnosed with liver disease. The supportive regulatory environment provided by the USFDA for the manufacturing of polyene phosphatidylcholine drug formulations further accentuates the market growth in the region. Europe is the second-largest regional market in the regional segment for the polyene phosphatidylcholine market. Affordable reimbursement scenario for the injectable and capsules containing polyene phosphatidylcholine determines its market growth in the region. The Asia Pacific is anticipated to be the fastest-growing regional segment for the polyene phosphatidylcholine market. Rising public health awareness and flourishing generic drug formulations market together propel the market growth in the Asia Pacific region.

Pharmaceutical manufacturers actively engaged in the production of polyene phosphatidylcholine are Sanofi-Aventis, Dutriec s.a. laboratorios, Alfresa Pharma, Haisco Pharmaceutical Group Co., Ltd, Chengdu Tiantaishan Pharmaceutical Co., Ltd, Nabros Pharma Pvt. Ltd., AMIpharm Co., Ltd., and Pharma Arte.

Key Market Movements:

  • Rising prevalence of hepatic disorders worldwide
  • Increasing demand for polyene phosphatidylcholine as a dietary supplement owing to its lipotropic effects further accentuates the market growth
  • Affordable reimbursement scenario or the drug formulation of polyene phosphatidylcholine provides positive thrust to its market growth

About Atlantic Market Research

Atlantic Market Research is the largest provider of market research and consulting services.

Research and consulting services of Atlantic Market Research help businesses across the globe navigate the challenges in a rapidly growing marketplace with confidence. Our customized and syndicated market research reports deliver sufficient insights that drive sustainable growth.

Contact:
Mr. Trevor Wilson
Atlantic Market Research
911 Central Ave #268
Albany, NY 12206, USA

Website: https://www.atlanticmarketresearch.com
Email: [email protected]

Categories
Market Outlook Market Reports Market Research

Global Hematology Probes Market Is Expected to Grow At A CAGR of 10.1% from 2020 to 2027

Hematology probes are used in molecular diagnostic techniques such as RT-PCR, Fluorescence in situ hybridization (FISH), Amplification Refractory Mutation System (ARMS), etc. for the elucidation of different gene mutation and loci responsible for the occurrence of blood disorders.

Blood cancer is reigning the clinical application segment for the hematology probes market. According to the latest research citings provided by the World Health Organization, approximately 300,000 new cases of leukemia are reported annually throughout the globe, which is responsible for 2.8% of all the new cancer cases recorded worldwide. Further clinical investigation has revealed the global prevalence rate of leukemia is 14.1 per 100,000 people across the globe. Hematopathology is going to register steady market growth on account of the rising prevalence of genetic blood disorders such as clotting disorders, and thrombosis, etc. Biopharmaceutical companies are entirely focusing their R&D on the manufacturing of orphan drugs associated with the treatment of hematology disorders.

Browse the full report Hematology Probes Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027 at https://www.atlanticmarketresearch.com/hematology-probes-market

Presently, pathology laboratories are dominating the end-user segment for the hematology probes market. Rising public health awareness has resulted in the early screening and diagnosis of blood malignancies worldwide, additionally the funding provided by the non-governmental and corporate social responsibility of pharmaceutical giants in establishing pathology laboratories in poor countries. Research academia is expected to showcase comfortable market growth during the forecast period. Enhanced research and development activities conducted in medical universities to investigate new drug molecules for its therapeutic efficacy in the treatment of blood cancer.

North America is currently leading the geography segment for the hematology probes market. The growing incidence of genetic blood disorders primarily drives market growth in the region. According to the latest statistics provided by the National Hemophilia Foundation (NHF), approximately 20,000 people are suffering from hemophilia in the United States. Additionally, the presence of major players such as Abbott Laboratories., Creative Bioarray, BioGenex, etc. further accentuates the market growth in the region. Europe is placed in the 2nd place in the regional segment for hematology probes on account of the rising prevalence of blood cancer in the region. As per the latest information provided by the European Journal of Cancer (EJC) by 2025, it is estimated that approximately 46,000 patients will be suffering from myeloma in the region. The Asia Pacific is anticipated to be the fastest-growing regional segment in the hematology probes market. Constant growth observed in the pathology laboratories and the emergence of local players engaged in the manufacturing of hematology probes together determine the market growth in the region.

Biopharmaceutical manufacturers actively engaged in the production of hematology probes are Abbott Laboratories, Creative Bioarray, BioGenex, Cytocell (Oxford Gene Technology), Biocare Medical, LLC., ZytoVision GmbH, SITOGEN, MetaSystems Probes GmbH, Generon., and NeoGenomics Laboratories, Inc.

Key Market Movements:

  • Rising prevalence of blood cancer worldwide
  • Growing incidence of blood malignancies such as hemophilia, thalassemia, etc. throughout the globe
  • Proactive role adopted by the government healthcare agencies in the early screening and diagnosis of blood disorders and prescribe appropriate treatment regimen for its treatment

About Atlantic Market Research

Atlantic Market Research is the largest provider of market research and consulting services.

Research and consulting services of Atlantic Market Research help businesses across the globe navigate the challenges in a rapidly growing marketplace with confidence. Our customized and syndicated market research reports deliver sufficient insights that drive sustainable growth.

Contact:
Mr. Trevor Wilson
Atlantic Market Research
911 Central Ave #268
Albany, NY 12206, USA

Website: https://www.atlanticmarketresearch.com
Email: [email protected]

Categories
Market Outlook Market Reports Market Research

Global Plasminogen Market Is Expected To Grow At A CAGR Of 4.1% From 2020 To 2027

Plasminogen is an inactive form of plasmin released by the liver in the systemic circulation, it is a serine protease and its objective is the dissolution of fibrin blood clots. Acquired and hereditary plasminogen deficiency increases the risk of thromboembolic disease.

Thrombosis is dominating the application segment for the plasminogen market. Rising prevalence of pulmonary embolism in elderly patients and a significant increase in the inherited plasminogen deficiency of plasminogen together drive the market growth.  As per the recent research findings provided by the World Health Organization (WHO), the prevalence rate associated with deep vein thrombosis is 1 to 2 per 1000 people each year. Ischemic heart disease will be showcasing remarkable market growth during the forecast period owing to the constant rise in the adoption of an unhealthy lifestyle, diet, stress, and high consumption of tobacco and alcohol worldwide. As per the latest research citings provided by the World Health Organization (WHO), approximately 15 million people suffer from stroke throughout the globe each year.

Hospitals and clinics are presently leading the end-user segment for the plasminogen market. The key factor responsible for its positive market growth is the rising prevalence of ischemic heart diseases and venous thromboembolism worldwide. Patients need to be immediately hospitalized in the critical care unit to remove the clot present in the venous system to prevent fatality and mortality associated with the disease. Ambulatory surgical centers will be growing at a rampant market growth in the near future to its ability to provide emergency medical aid to patients suffering from myocardial infarction in remote locations.

Browse the full report Plasminogen Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027 at https://www.atlanticmarketresearch.com/plasminogen-market

North America is currently spearheading the geography segment for the plasminogen market. The major factor associated with its market dominance is the rising prevalence of deep vein thrombosis in the region. According to the latest statistics provided by the Center for Disease Control and Prevention (CDC), approximately the prevalence rate associated with deep vein thrombosis is 1 to 2 per 1,000 per year in the United States. Affordable reimbursement scenario and supportive regulatory environment provided by the USFDA pertaining to the manufacture and sale of plasminogen provides a boost to the market growth in the region. Europe stood 2nd in the regional segment for the plasminogen market on account of the rising prevalence of ischemic heart disease in the European Union. As per the latest research citings presented by the European Heart Network (EHN), each year cardiovascular disease causes approximately 3.9 million deaths in the region. Asia Pacific is anticipated to be the fastest-growing regional segment during the forecast period owing to the developing healthcare infrastructure and constant rise in the medical tourism industry in the Asia Pacific region.

Biopharmaceutical manufacturers actively engaged in the production of plasminogen are Diapharma, Kedrion S.p.A., Liminal BioSciences, Genentech, Inc. (Roche), Boehringer Ingelheim, Kyowa Hakko Kirin, Omeros Corporation, Bayer AG, Cadila Healthcare Ltd, and Merck & Co.

Market Key Takeaway:

  • Rising prevalence of ischemic heart diseases worldwide
  • Significant increase in the number of people suffering from venous thromboembolism throughout the globe
  • The supportive regulatory environment provided by the global healthcare agencies regarding the manufacturing and sale of plasminogen

About Atlantic Market Research

Atlantic Market Research is the largest provider of market research and consulting services.

Research and consulting services of Atlantic Market Research help businesses across the globe navigate the challenges in a rapidly growing marketplace with confidence. Our customized and syndicated market research reports deliver sufficient insights that drive sustainable growth.

Contact:
Mr. Trevor Wilson
Atlantic Market Research
911 Central Ave #268
Albany, NY 12206, USA

Website: https://www.atlanticmarketresearch.com
Email: [email protected]

Categories
Market Outlook Market Reports Market Research

Global Silicone Foam Dressings Market is expected to grow at a CAGR of 15.2% from 2020 to 2027

Silicone foam dressings are gaining tremendous demand for treating chronic and acute wounds due to the excellent ergonomic properties associated with it such as superior moisture vapor transmission rate and absorbency. The adequate porosity permits the exchange of gas and prevents the microbial invasion at the site of injury. Silicone foam dressings are critical in maintaining a moist environment to facilitate healing. Multilayered silicone foam dressings are employed in wound treatment owing to its ability to be safely removed without causing any tissue trauma, pain, or discomfort. The exorbitant cost associated with silicone foam dressings might serve as a limitation for its market growth.

Surgical wounds are dominating the application segment for the silicone foam dressings market. A constant rise in the number of surgeries performed worldwide as the only treatment option for chronic ailments and the looming threat of surgical site infections provide a potential market for silicone foam dressing market. Ulcers are anticipated to register rampant growth during the forecast period owing to the rising prevalence of diabetic foot ulcers and pressure ulcers worldwide. Skin burns are on a constant rise on account of occupational hazards and fire accidents.

Browse the full report Silicone Foam Dressings Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027 at https://www.atlanticmarketresearch.com/silicone-foam-dressings-market

Hospitals and clinics are spearheading the end-user segment for the silicone foam dressings market. The significant rise in diabetic patients suffering from foot ulcers and the growing incidence of pressure ulcers will determine the market dominance of hospitals & clinics. Ambulatory surgical centers are gaining tremendous traction on account of its ability to rescue patients in remote locations suffering from chronic wounds inflicted by occupation hazards.

In the current scenario, North America is accountable for the largest market share in the geography segment for the silicone foam dressings market. As per the latest research citings provided by the Center for Disease Control and Prevention (CDC) each year approximately 6.5 million U.S. citizens are treated for chronic wounds. The rising prevalence of chronic wounds and affordable reimbursement scenarios together determine the silicon foam market growth in the region. In Europe the market growth is majorly driven by the growing incidence of diabetic foot ulcers in patients suffering from diabetes. According to the latest statistics brought forwards by the CORDIS report of the European Commission approximately 8 million people in Europe are at the risk of developing diabetic foot ulcers in some stage of their life which provides a potential market for silicone foam dressings market. The supportive regulatory environment provided by the European Medical Agency for the early CE approval of silicone foam dressings further accentuates the market growth in the region. In Asia Pacific the market growth is majorly dependent on a significant rise in the chronic wounds inflicted by road accidents and occupational hazards, furthermore developing healthcare infrastructure will further propel the market growth in the Asia Pacific region.

Biomedical companies engaged in the production of silicone foam dressings are Advanced Medical Solutions Limited, Convatec, Inc., Coloplast Corp., DermaRite Industries, LLC., Biotronix Healthcare, Inc., 3M Company, Cardinal Health, Mölnlycke Health Care AB., MPM Medical, LLC., Covalon Technologies, Ltd.

Market Key Takeaways:

  • Rising prevalence of diabetic foot ulcer and pressure ulcer throughout the globe
  • Significant rise in the surgical procedures performed worldwide associated with chronic diseases and an increase in the number of skin burn cases
  • Technological advancement in the development of multilayered silicone foam dressings with superior MVT and absorbency rate to promote wound healing

About Atlantic Market Research

Atlantic Market Research is the largest provider of market research and consulting services.

Research and consulting services of Atlantic Market Research help businesses across the globe navigate the challenges in a rapidly growing marketplace with confidence. Our customized and syndicated market research reports deliver sufficient insights that drive sustainable growth.

Contact:
Mr. Trevor Wilson
Atlantic Market Research
911 Central Ave #268
Albany, NY 12206, USA

Website: https://www.atlanticmarketresearch.com
Email: [email protected]